In the imbalanced intestinal immune microenvironment of IBD patients, inflammatory mediators, and cytokines released by a large number of inflammatory cells can activate the Janus kinase 2 (JAK2) signaling pathway to aggravate the damage of the intestinal tract and intestinal barrier function. Here, JAK2 is linked to inflammatory bowel disease.